DDInter575 DDInter1652
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Disopyramide {u} (Compound) resembles {v} (Compound) Dextropropoxyphene
Disopyramide {u} (Compound) resembles {v} (Compound) Isopropamide
Disopyramide {u} (Compound) binds {v} (Gene) CHRM2
Disopyramide {u} (Compound) upregulates {v} (Gene) KIAA0355
Disopyramide {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Disopyramide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylprednisolone
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Abarelix
Disopyramide (Compound) resembles Dextropropoxyphene (Compound)
Disopyramide (Compound) resembles Isopropamide (Compound)
Disopyramide (Compound) binds CHRM2 (Gene)
Disopyramide (Compound) upregulates KIAA0355 (Gene)
Disopyramide (Compound) causes Cardiac arrest (Side Effect)
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human
Disopyramide may lead to a major life threatening interaction when taken with Entrectinib
Disopyramide may lead to a major life threatening interaction when taken with Abarelix